| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2005;80:149-152
© 2005 The Society of Thoracic Surgeons
a Department of Cardiothoracic Surgery, Northern General Hospital, Sheffield, United Kingdom
b Cardiovascular Research Group, University of Sheffield, Sheffield, United Kingdom
Accepted for publication January 3, 2005.
* Address reprint requests to Dr Cooper, Northern General Hospital, Herries Rd, Sheffield, United Kingdom S57AU (Email: graham.cooper{at}sth.nhs.uk).
BACKGROUND: The optimal management of aspirin and clopidogrel therapy before surgery in patients with acute coronary syndrome is uncertain. Aspirin and clopidogrel within 5 days of surgery increases postoperative bleeding and reexploration. However, in acute coronary syndrome patients the risk of bleeding must be balanced against the risks of discontinuing the treatment and delaying surgery.
METHODS: From June 2002 to July 2003, patients undergoing urgent coronary artery bypass graft surgery (CABG) for acute coronary syndrome were randomly assigned to one of two groups. The treatment group remained on aspirin and clopidogrel therapy till surgery, receiving intraoperative aprotinin. The placebo group received placebo for 5 days before surgery and received placebo infusions intraoperatively. Platelet reactivity in response to adenosine diphosphate was assessed by whole blood single-platelet counting. Of the 88 patients eligible, 50 entered the study.
RESULTS: Postoperative blood loss was significantly greater in the placebo group than in the treatment group (702 ± 120 mL versus 446 ± 62 mL, p = 0.004). This difference was observed as early as 8 hours postoperatively (385 ± 66 mL versus 266 ± 36 mL, p = 0.03). Patients in the placebo group also required more blood transfusions (1 ± 0.3 units versus 0.3 ± 0.2 units, p = 0.03). Three patients in each group underwent surgical reexploration for bleeding.
CONCLUSIONS: The strategy of continuing aspirin and clopidogrel therapy with intraoperative aprotinin reduces postoperative blood loss, transfusion requirements, prevents delay to surgical treatment, and may prevent major adverse cardiac events before surgery.
This article has been cited by other articles:
|
|
 |
|
  J. M. O'Riordan, R. J. Margey, G. Blake, and P. R. O'Connell Antiplatelet Agents in the Perioperative Period Arch Surg, January 1, 2009; 144(1): 69 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lindvall, U. Sartipy, T. Ivert, and J. van der Linden Aprotinin is Not Associated With Postoperative Renal Impairment After Primary Coronary Surgery Ann. Thorac. Surg., July 1, 2008; 86(1): 13 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Bittner, J. Lemke, M. Lange, A. Rastan, and F. W. Mohr The Impact of Aprotinin on Blood Loss and Blood Transfusion in Off-Pump Coronary Artery Bypass Grafting Ann. Thorac. Surg., May 1, 2008; 85(5): 1662 - 1668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Howard-Alpe, J. de Bono, L. Hudsmith, W. P. Orr, P. Foex, and J. W. Sear Coronary artery stents and non-cardiac surgery Br. J. Anaesth., May 1, 2007; 98(5): 560 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ouattara, H. Bouzguenda, Y. Le Manach, P. Leger, A. Mercadier, P. Leprince, N. Bonnet, G. Montalescot, B. Riou, and P. Coriat Impact of aspirin with or without clopidogrel on postoperative bleeding and blood transfusion in coronary surgical patients treated prophylactically with a low-dose of aprotinin Eur. Heart J., April 12, 2007; (2007) ehm049v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Poston Letter by Poston Regarding Article, "Effect of Clopidogrel Premedication in Off-Pump Cardiac Surgery: Are We Forfeiting the Benefits of Reduced Hemorrhagic Sequelae?" Circulation, November 14, 2006; 114(20): e589 - e589. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
